8-K: Celcuity Announces Second Quarter 2024 Financial Results and Provides Corporate Update

Celcuity reported its second quarter 2024 financial results, highlighted by a $129 million capital raise and progress in its clinical trials, including the initiation of a Phase 3 trial for gedatolisib.

Summary

• Celcuity announced its financial results for the second quarter ended June 30, 2024, and provided a corporate update.
• The company raised $129 million in gross proceeds through equity and debt financings, extending its operational runway through 2026.
• Celcuity plans to initiate the Phase 3 VIKTORIA-2 trial for gedatolisib as a first-line treatment for HR+, HER2advanced breast cancer, with the first patient expected to be enrolled in Q2 2025.
• The company expects to reach the enrollment target for the VIKTORIA-1 PIK3CA wild-type cohort in Q4 2024 and report topline data in late Q4 2024 or Q1 2025.
• Total operating expenses for the quarter were $24.3 million, compared to $15.1 million in the same period last year.
• Research and development expenses increased to $22.5 million from $13.8 million year-over-year, primarily due to activities supporting the VIKTORIA-1 trial and the initiation of the CELC-G-201 trial.
• The net loss for the quarter was $23.7 million, or $0.62 loss per share, compared to a net loss of $14.6 million, or $0.66 loss per share, in the second quarter of 2023.
• Non-GAAP adjusted net loss was $22.2 million, or $0.58 loss per share, compared to $11.1 million, or $0.51 loss per share, in the prior year period.
• Net cash used in operating activities was $18.1 million for the quarter, compared to $9.7 million in the second quarter of 2023.
• As of June 30, 2024, Celcuity had $283.1 million in cash, cash equivalents, and short-term investments.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive due to the successful capital raise and progress in clinical trials, but tempered by the increased net loss and delay in topline data.

Positives

• The company successfully raised $129 million, providing financial stability and extending the operational runway through 2026.
• The initiation of the Phase 3 VIKTORIA-2 trial represents a significant step forward in the development of gedatolisib.
• Enrollment in the VIKTORIA-1 trial is progressing well, with the PIK3CA wild-type cohort more than 80% complete.
• The company has a strong cash position of $283.1 million.
• Three manuscripts reporting clinical and nonclinical results for gedatolisib were published recently.

Negatives

• The net loss for the quarter increased to $23.7 million, compared to $14.6 million in the same period last year.
• Research and development expenses increased significantly to $22.5 million, impacting profitability.
• The timeline for topline data for the VIKTORIA-1 PIK3CA wild-type cohort has shifted from Q3 2024 to late Q4 2024 or Q1 2025.
• The proportion of patients with PIK3CA wild-type tumors in the VIKTORIA-1 study has shifted lower than originally estimated.

Risks

• The company faces risks associated with clinical trial delays, regulatory approvals, and market acceptance of its products.
• There is a risk of competition from other therapies and tools.
• The company's ability to access capital on favorable terms is not guaranteed.
• The shift in the timeline for topline data for the VIKTORIA-1 PIK3CA wild-type cohort could impact investor sentiment.
• The increased operating expenses and net loss could raise concerns about the company's financial sustainability.

Future Outlook

Celcuity expects to reach the enrollment target for the VIKTORIA-1 PIK3CA wild-type cohort in Q4 2024 and report topline data in late Q4 2024 or Q1 2025. The company also plans to initiate the Phase 3 VIKTORIA-2 trial in Q2 2025 and expects to report preliminary data from the Phase 1b/2 trial for mCRPC in the first half of 2025.

Management Comments

• Brian Sullivan, CEO and co-founder of Celcuity, stated that they made significant strides advancing the clinical development of gedatolisib this quarter.
• Brian Sullivan also noted that overall enrollment in VIKTORIA-1 remains robust and on-track relative to previous projections.

Industry Context

This announcement is relevant to the biotechnology and oncology sectors, particularly companies focused on developing targeted therapies for breast cancer. The progress of Celcuity's gedatolisib program is being closely watched by investors and competitors in the space.

Comparison to Industry Standards

• Celcuity's increased R&D spending is typical for a clinical-stage biotech company advancing multiple trials.
• The $129 million capital raise is significant and positions the company well compared to peers with less funding.
• The shift in the timeline for topline data is not uncommon in clinical trials, but it is important to monitor the impact on investor confidence.
• Companies like Novartis, Pfizer, and Eli Lilly are also developing treatments for HR+/HER2breast cancer, making this a competitive space.

Stakeholder Impact

• Shareholders will be impacted by the financial results and clinical trial progress.
• Employees will be affected by the company's financial performance and operational activities.
• Patients with HR+/HER2advanced breast cancer may benefit from the development of gedatolisib.
• Creditors will be impacted by the company's debt financing activities.

Next Steps

• Celcuity will continue to enroll patients in the VIKTORIA-1 and CELC-G-201 trials.
• The company will initiate the Phase 3 VIKTORIA-2 trial in Q2 2025.
• Celcuity will report topline data for the VIKTORIA-1 PIK3CA wild-type cohort in late Q4 2024 or Q1 2025.
• The company will report preliminary data from the Phase 1b/2 trial for mCRPC in the first half of 2025.

Key Dates

Keywords

gedatolisib, breast cancer, clinical trial, VIKTORIA-1, VIKTORIA-2, PIK3CA, HR+, HER2-, oncology, biotechnology, financial results, capital raise